. Author manuscript; available in PMC: 2015 May 27.

Published in final edited form as: Br J Haematol. 2013 Sep 24;163(4):436–443. doi: 10.1111/bjh.12573

Table I.

Preclinical and phase I study data.

Agent	ONO-WG-307	LFM-A13	Dasatinib	CC-292	Ibrutinib
Developer	ONO Pharmaceutical	University of Southern California	Bristol-Myers Squibb	Celgene Corporation	Pharmacyclics and Janssen Pharmaceuticals
Mechanism, Target	Reversible, Tyr223	Reversible, Unknown	Reversible, Unknown	Irreversible, Cys481	Irreversible, Cys481
Potency	IC₅₀ = 2 nmol/l	IC₅₀ = 7·5 μmol/l	IC₅₀ = 5 nmol/l	IC₅₀ <0·5 nmol/l	IC₅₀ = 0·5 nmol/l
Clinical Data From Phase I Trials in Relapsed/Refractory B Cell Malignancies	N/A	N/A	Multiple Histologies n = 19 ORR 32%, CR 11%	Multiple Histologies n = 17 SD: 94%, PR: 6% CLL n = 50 ORR 34%, CR 0%	Multiple Histologies n = 56 (% ORR/CR) MCL: 78/33 CLL/SLL: 69/13 FL: 55/27 DLBCL: 29/0 WM: 75/0 MZL: 25/0

B-NHL, B cell non-Hodgkin lymphoma; CLL, chronic lymphocytic leukaemia; SLL, small lymphocytic lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; WM, Waldenström macroglobulinaemia; ORR, objective response rate; CR, complete response; PR, partial response; PFS, progression-free survival; R/R, relapsed/refractory; N/A: not available.